No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ADUS240517P55000
- 0.15
- 0.000.00%
15min DelayClose Apr 19 12:06 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume1 Open Interest55.00Strike Price0.00Turnover4032.77%IV-50.43%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type-0.0109Delta0.0008Gamma737.73Leverage Ratio-19.5875Theta0.0000Rho-8.00Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Addus HomeCare Is Maintained at Buy by TD Cowen
Addus HomeCare Is Maintained at Buy by TD Cowen
TD Cowen Maintains Buy on Addus HomeCare, Raises Price Target to $119
TD Cowen analyst Ryan Langston maintains Addus HomeCare (NASDAQ:ADUS) with a Buy and raises the price target from $105 to $119.
Express News | Arex Capital Expresses Disappointment in Enhabit’s Strategic Review Conclusion
Express News | Addus Homecare Corp : TD Cowen Raises Target Price to $119 From $105
Express News | Addus Homecare Corp : Raymond James Raises Target Price to $115 From $105
Here's Why We Think Addus HomeCare (NASDAQ:ADUS) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit.
Comments
Addus HomeCare's rising ROCE and capital employed are positive signs. The stock's past five-year performance suggests investors may be overlooking these promising trends, indicating potential investment opportunities.
Returns Are Gaining Momentum At Addus HomeCare (NASDAQ:ADUS)The stock is undervalued, presenting a buying opportunity as future growth isn't fully reflected in the price. Consider the company's capital structure and management record before investing.
1
Insiders' lack of purchases last year may concern investors, but their ownership indicates alignment with investors. The largest recent insider sale matching the current share price could hint at limited growth. However, investment decisions shouldn't rely solely on directors' actions.
Addus HomeCare's rising ROCE and regular business investment make it a worthwhile consideration for investors. Its capacity to boost returns while expanding capital hints at future growth possibilities. Despite recent 27% return to shareholders, the company's growth potential may still be underestimated.
Upgrades
• $Booz Allen Hamilton Holding Corp(BAH.US$: Goldman Sachs Upgrades to Buy from Neutral - PT $102 (from $83)
• $Humana(HUM.US$: UBS Upgrades to Buy from Neutral - PT $520 (from $486)
• $JB Hunt Transport Services(JBHT.US$: Deutsche Bank Upgrades to Buy from Hold - PT $230 (from $210)
Downgrades
• $JB Hunt Transport Services(JBHT.US$: B.Riley Downgrades to Neutral from Buy - PT $33 (from $62)
• $CACI International(CACI.US$: Goldman Sachs Downgrad...
• $Booz Allen Hamilton Holding Corp(BAH.US$: Goldman Sachs Upgrades to Buy from Neutral - PT $102 (from $83)
• $Humana(HUM.US$: UBS Upgrades to Buy from Neutral - PT $520 (from $486)
• $JB Hunt Transport Services(JBHT.US$: Deutsche Bank Upgrades to Buy from Hold - PT $230 (from $210)
Downgrades
• $JB Hunt Transport Services(JBHT.US$: B.Riley Downgrades to Neutral from Buy - PT $33 (from $62)
• $CACI International(CACI.US$: Goldman Sachs Downgrad...
9
2
?Read more